Qiming Venture Partners Portfolio Companies UBTECH and Biren Technology Named to 2026 Fortune Future 120

The 2026 Fortune Future 120 list has been released, recognizing companies worldwide with the greatest capacity for sustained, long-term growth. Two Qiming Venture Partners portfolio companies — UBTECH (09880.HK) and Biren Technology (06082.HK) — made the cut, ranking 11th and 46th globally, respectively. UBTECH is the highest-ranked Chinese company on this year's list.

UBTECH and Biren Technology

Named to

2026 Fortune Future 120

The Fortune Future 120 is jointly published by Fortune magazine and Boston Consulting Group (BCG), building on the Fortune Future 50 list the two organizations launched in 2017. While the Future 50 assessed future growth potential among large public companies, the expanded 120 list covers both public and private firms, with the goal of identifying businesses with the strongest long-term growth potential globally.

To qualify, public companies must have a market cap of at least $5 billion; private companies must have raised at least $1 billion in cumulative funding since founding, or employ more than 20,000 people. Over 3,500 eligible companies were evaluated this year.

The ranking draws on three dimensions — growth ambition, talent density, and growth culture — and uses 15 forward-looking indicators tied to long-term revenue growth to score and rank companies. A total of 11 Chinese companies made this year's list.

Source | Fortune

Past Coverage

Qiming Honors | Qiming Venture Partners Investors and Founders Named to 36Kr Dark Current Waves 2026 36 Under 36 List Qiming Stars | Pluslife Founder Yangzhou Song Named to TIME100 Health 2026 Qiming Headlines | Qiming Venture Partners Partner Alex Zhou Named to Forbes 2026 Midas List | Bilingual

Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.

To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies. More than 210 of these have gone public on exchanges including the NYSE, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A. Over 80 portfolio companies have become recognized unicorns or super-unicorns.

Many Qiming portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 0800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu AI (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), APT Medical (688617.SH), Sanyou Medical (688085.SH), AmoyDx (300685.SZ), Sinocelltech (688520.SH), Insilico Medicine (03696.HK), AusperBio, Yuanxin Technology, MediLink Therapeutics, Leads Biolabs, and StepFun.